Search results
Showing 286 to 300 of 489 results for 2011
Biographies and registered interests for members of the Technology Appraisal Committee C
Discontinued Reference number: GID-TAG436
This quality standard covers the identification and management of familial and genetic risk and the recognition and management of ovarian, fallopian tube and primary peritoneal cancer or borderline ovarian cancer in women, trans men and non-binary people aged 18 and over with female reproductive organs (ovaries, fallopian tubes or a uterus). It describes high-quality care in priority areas for improvement.
View quality statements for QS18Show all sections
Sections for QS18
- Quality statements
- Quality statement 1: Discussion about risk-reducing surgery
- Quality statement 2 (placeholder): CA125 blood test – age-specific thresholds
- Quality statement 3: Panel germline genetic testing for non-mucinous high-grade epithelial ovarian cancer
- Quality statement 4: Tumour genetic testing for stage 3 or 4 non-mucinous high-grade epithelial ovarian cancer
- Quality statement 5: Treatment of high-risk stage 1 or stage 2 to 4 ovarian cancer
- Update information
- About this quality standard
This quality standard covers road-traffic-related air pollution and its impact on health. It describes high-quality actions in priority areas for improvement.
View quality statements for QS181Show all sections
Sections for QS181
- Quality statements
- Quality statement 1: Strategic plans
- Quality statement 2: Planning applications
- Quality statement 3: Reducing emissions from public sector vehicle fleets
- Quality statement 4: Advice for people with chronic respiratory or cardiovascular conditions
- Update information
- About this quality standard
This quality standard covers recognising, assessing and responding to abuse and neglect of children and young people under 18. It covers physical, sexual and emotional abuse. This quality standard describes high-quality care in priority areas for improvement.
Lymphoma (non Hodgkin's, peripheral T-cell) - pralatrexate [ID368]
Discontinued Reference number: GID-TAG424
Discontinued Reference number: GID-TAG422
Discontinued Reference number: GID-TAG427
This guideline covers safe midwifery staffing in all maternity settings, including at home, in the community, in day assessment units, in obstetric units, and in units led by midwives (both alongside hospitals and free-standing). It aims to improve maternity care by giving advice on monitoring staffing levels and actions to take if there are not enough midwives to meet the needs of women and babies in the service.
This guideline sets out an antimicrobial prescribing strategy for human and animal bites (excluding insect bites) in adults, young people and children aged 72 hours and over. It aims to optimise antibiotic use and reduce antibiotic resistance.
High-throughput non-invasive prenatal testing for fetal RHD genotype (HTG420)
Evidence-based recommendations on high-throughput non-invasive prenatal testing (NIPT) for fetal RHD genotype.
i STAT CG4+ and CHEM8+ cartridges for point-of-care testing in the emergency department (MIB38)
NICE has developed a medtech innovation briefing (MIB) on i STAT CG4+ and CHEM8+ cartridges for point-of-care testing in the emergency department
November 2011 On 25 October 2011, Eli Lilly and Company announced the withdrawal of its Xigris (drotrecogin alfa [activated]) product in all markets following results of the PROWESS–SHOCK study, which showed the study did not meet the primary endpoint of a statistically significant reduction in 28-day all-cause mortality in patients with septic shock. The company is working with regulatory agencies on this withdrawal, and is in the process of notifying healthcare professionals and clinical trial investigators. As a result of this, NICE has withdrawn its guidance on the use of drotrecogin alfa (activated) for severe sepsis.
Bosutinib for previously treated chronic myeloid leukaemia (TA401)
Evidence-based recommendations on bosutinib (Bosulif) for previously reated chronic myeloid leukaemia in adults.
Discontinued Reference number: GID-TAG421